Comparison of the inhibitory effect of topical cyclosporine A 0.1% and topical anti-VEGF application in an experimental model of corneal neovascularization

Introduction: Normally the cornea in human eye is crystalline clear membranepresent in the anterior most portion of the eyeball. Regarding the various functions of thecornea in human eye it provides protection, clear vision, refractive media the visual systemand maintains itself as an immune privileged site. Neovascularization is mostly associated withan inflammation and always indicate a state of disease. Similarly Corneal Neovascularizationcan cause Graft rejection reaction after keratoplasty the different types of anti-VEGF agentsnow are used to prevent neovascular eye diseases. These different Anti-VEGF inhibitors areLucentis, Macugen and bevacizumab/Avastin and used in case of ocular neovascularization.Objectives: To determine the efficacy of subconjuctival injection of Avastin on patients havingcorneal neovascularization following keratoplasty. Settings: Department of OphthalmologyAllied Hospital, Faisalabad and Independent University Hospital, Faisalabad. Study Duration:The duration of study was 11-02-2015 to 11-07-2015. Results: A total of 86 cases fulfilling theinclusion/exclusion criteria were enrolled to determine the efficacy of subconjuctival injectionof Avastin on patients having corneal neovascularization following keratoplasty. Discussion:Regarding the success of Keratoplasty is determined by many factors especially avascularity ofcornea after surgery. Corneal neovasculrization is disease process secondary to various ocularinsults in which growth of vessels towards central cornea occur from the limbal vascular plexus.But now a days Bevacizumab/Avastin is commonly used in Ophthalmology as “off label” drug inthe treatment of Exudative age related macular degeneration as well as in diabetic retinopathy.Conclusion: We concluded that the frequency of efficacy of subconjuctival bevacizumab ishigher in patients having corneal neovascularization after corneal transplantation.

Download Full-text

Treating Severe Pediatric Keratoconjunctivitis with Topical Cyclosporine A

Klinische Monatsblätter für Augenheilkunde ◽

10.1055/a-1556-1182 ◽

2021 ◽

Author(s):

Julia Biermann ◽

Friederike Bosche ◽

Nicole Eter ◽

Flemming Beisse

Keyword(s):

Cyclosporine A ◽

Treatment Plan ◽

Corneal Opacity ◽

Corneal Neovascularization ◽

Visual Development ◽

Vernal Keratoconjunctivitis ◽

Upper Eyelid ◽

Sparing Effect ◽

One Year

AbstractThe incidence of chronic keratoconjunctivitis, which potentially causes long-term loss of visual acuity due to corneal opacity, is considerably less common in children than in adults. It is therefore in danger of being overlooked. In children the appropriate treatment is therefore often introduced too late, or to an insufficient extent. In this article we would like to raise awareness about the diagnosis of chronic keratoconjunctivitis in children, and to present an effective treatment plan for severe stages of the disease. There are two forms of chronic keratoconjunctivitis that occur most frequently in children: hyperergic blepharokeratoconjunctivitis (hBKC) and vernal keratoconjunctivitis (VKC). With hBKC, the patient often has a history of recurring hordeolum and also presents with blepharitis; it is characterized by the marked presence of corneal neovascularization in the lower circumference of the cornea. VKC is typically characterized by changes under the upper eyelid, with marked changes to the superior limbus. If there is a risk of complications involving the cornea, or in the presence of such complications, a consistent long-term topical immunosuppressive and anti-inflammatory treatment is required. Both of these properties are combined in the active ingredient cyclosporine A. Other advantages of topical CSA treatment are its steroid-sparing effect and the long-term reduction of exacerbations. Parents need to be informed about the chronic nature of these two diseases and their tendency to recur; because of these characteristics, treatment, in most cases, should be envisaged for at least one year in order to effectively disrupt the complex immunologic processes. This safeguards the childʼs visual development and prevents amblyopia caused by scarring and astigmatism. We hope that the data presented will lower the barriers related to prescribing CSA for topical eye application in children.

Download Full-text

Inhibitory Effect of Curcumin on Corneal Neovascularization in vitro and in vivo

Ophthalmologica ◽

10.1159/000126081 ◽

2008 ◽

Vol 222 (3) ◽

pp. 178-186 ◽

Cited By ~ 12

Author(s):

Fang Bian ◽

Ming-Chang Zhang ◽

Yun Zhu

Keyword(s):

Corneal Neovascularization ◽

Inhibitory Effect

Download Full-text

Inhibitory Effect of Canstatin in Alkali Burn-Induced Corneal Neovascularization

Ophthalmic Research ◽

10.1159/000322804 ◽

2011 ◽

Vol 46 (2) ◽

pp. 66-72 ◽

Cited By ~ 8

Author(s):

Ye Wang ◽

Hongmei Yin ◽

Peng Chen ◽

Lixin Xie ◽

Yiqiang Wang

Keyword(s):

Corneal Neovascularization ◽

Inhibitory Effect ◽

Alkali Burn

Download Full-text

Treating corneal neovascularization using a combination of anti-VEGF injection and argon laser photocoagulation application - case report

Romanian Journal of Ophthalmology ◽

10.22336/rjo.2021.58 ◽

2021 ◽

Vol 65 (3) ◽

pp. 286-289

Author(s):

Mariela Grossi Donato ◽

Elias Donato ◽

Marina Álvares de Campos Cordeiro ◽

Matheus Martins de Andrade ◽

João Alberto Holanda de Freitas

Keyword(s):

Case Report ◽

Laser Photocoagulation ◽

Argon Laser ◽

Corneal Neovascularization ◽

Anti Vegf ◽

Argon Laser Photocoagulation

Download Full-text

RIP1 kinase mediates angiogenesis by modulating macrophages in experimental neovascularization

Proceedings of the National Academy of Sciences ◽

10.1073/pnas.1908355116 ◽

2019 ◽

Vol 116 (47) ◽

pp. 23705-23713 ◽

Cited By ~ 5

Author(s):

Takashi Ueta ◽

Kenji Ishihara ◽

Shoji Notomi ◽

Jong-Jer Lee ◽

Daniel E. Maidana ◽

...

Keyword(s):

Kinase Activity ◽

Inflammatory Cells ◽

Corneal Neovascularization ◽

Inhibitory Effect ◽

Interleukin 4 ◽

Caspase Activation ◽

Interacting Protein ◽

Pathological Angiogenesis ◽

Caspase Inhibition

Inflammation plays an important role in pathological angiogenesis. Receptor-interacting protein 1 (RIP1) is highly expressed in inflammatory cells and is known to play an important role in the regulation of apoptosis, necroptosis, and inflammation; however, a comprehensive description of its role in angiogenesis remains elusive. Here, we show that RIP1 is abundantly expressed in infiltrating macrophages during angiogenesis, and genetic or pharmacological inhibition of RIP1 kinase activity using kinase-inactive RIP1K45A/K45A mice or necrostatin-1 attenuates angiogenesis in laser-induced choroidal neovascularization, Matrigel plug angiogenesis, and alkali injury-induced corneal neovascularization in mice. The inhibitory effect on angiogenesis is mediated by caspase activation through a kinase-independent function of RIP1 and RIP3. Mechanistically, infiltrating macrophages are the key target of RIP1 kinase inhibition to attenuate pathological angiogenesis. Inhibition of RIP1 kinase activity is associated with caspase activation in infiltrating macrophages and decreased expression of proangiogenic M2-like markers but not M1-like markers. Similarly, in vitro, catalytic inhibition of RIP1 down-regulates the expression of M2-like markers in interleukin-4–activated bone marrow-derived macrophages, and this effect is blocked by simultaneous caspase inhibition. Collectively, these results demonstrate a nonnecrotic function of RIP1 kinase activity and suggest that RIP1-mediated modulation of macrophage activation may be a therapeutic target of pathological angiogenesis.

Download Full-text